In early 2025, as part of the Sever project, Izvarino Pharma, a Moscow-based company, will commence the production of pharmaceutical substances in Kazan. The production facility situated within the industrial park of Kazan Federal University (KFU) will focus on the complete manufacturing cycle of medications specifically for oncology and transplantology.
The investment volume of the project reaches 1.1 billion rubles, with 700 million already spent. The initiative is aimed at strengthening Russia’s pharmaceutical independence in the field of critically important drugs. The production site, acquired by the company in 2023, will produce a number of drugs.
